| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,520 | 3,600 | 11.04. | |
| 3,500 | 3,600 | 10.04. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | CanSino Biologics Inc: CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader | 463 | JCN Newswire | HONG KONG, Mar 31, 2026 - (ACN Newswire) - HONG KONG, Mar 31, 2026 - (ACN Newswire) - China's 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry,... ► Artikel lesen | |
| 30.03. | CANSINOBIO (06185): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 17.03. | CANSINOBIO (06185): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 05.03. | CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - OBTAINMENT OF THE PIC/S GMP CERTIFICATE | 3 | HKEx | ||
| 26.02. | CANSINOBIO (06185): INSIDE INFORMATION - UPDATES ON 2025 PRELIMINARY ANNUAL RESULTS | - | HKEx | ||
| 24.02. | CanSino Biologics Inc: CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential | 422 | JCN Newswire | HONG KONG, Feb 24, 2026 - (ACN Newswire) - CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by... ► Artikel lesen | |
| CANSINO BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 24.02. | CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - MENHYCIA OBTAINS THE NOTIFICATION OF APPROVAL OF SUPPLEMENTAL DRUG APPLICATION | - | HKEx | ||
| 09.02. | CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines | 345 | PR Newswire | DUBAI, Feb. 9, 2026 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine at the World Government Summit... ► Artikel lesen | |
| 27.01. | CANSINOBIO (06185): INSIDE INFORMATION - RESULTS FORECAST FOR THE YEAR 2025 | 13 | HKEx | ||
| 05.01. | CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - PCV24 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA | 12 | HKEx | ||
| 19.12.25 | CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR DTCP-HIB-MCV4 COMBINED ... | 4 | HKEx | ||
| 27.11.25 | CANSINOBIO (06185): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 27.11.25 | CANSINOBIO (06185): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 27.11.25 | CANSINOBIO (06185): POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING; AMENDMENTS TO THE ARTICLES OF ASSOCIATION; ELECTION OF INDEPENDENT ... | 1 | HKEx | ||
| 27.11.25 | CANSINOBIO (06185): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 13.11.25 | CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR INHALED TB BOOSTER IN ... | - | HKEx | ||
| 11.11.25 | CANSINOBIO (06185): FORM OF PROXY FOR USE AT THE 2025 SECOND EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, NOVEMBER 27, 2025 | 1 | HKEx | ||
| 11.11.25 | CANSINOBIO (06185): NOTICE OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 11.11.25 | CANSINOBIO (06185): 2025 SECOND EGM CIRCULAR | - | HKEx | ||
| 07.11.25 | CANSINOBIO (06185): INSIDE INFORMATION - USING RESERVES TO OFFSET LOSSES | - | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| EVOTEC | 4,530 | +0,09 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen | |
| BB BIOTECH | 48,350 | 0,00 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | Valneva mit Rekordsignal: Was große Adressen zum Wochenstart bereits wissen - Was erfahrene Anleger jetzt analysieren | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| EPIGENOMICS | 0,920 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 289,50 | +0,10 % | Stryker confident of 2026 outlook despite Q1 impact from cyberattack | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| BIOFRONTERA | 2,610 | +2,35 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| HEIDELBERG PHARMA | 2,810 | +3,31 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen |